uniQure N.V. (NASDAQ:QURE) Receives $60.82 Consensus Target Price from Brokerages

uniQure N.V. (NASDAQ:QURE) has been given a consensus recommendation of “Moderate Buy” by the thirteen analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $60.8182.

Several brokerages recently commented on QURE. UBS Group set a $95.00 target price on uniQure in a report on Thursday, September 25th. Stifel Nicolaus lowered their price objective on shares of uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. Leerink Partners dropped their price objective on shares of uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a research note on Monday, November 10th. Wells Fargo & Company reduced their target price on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 12th. Finally, Wall Street Zen lowered shares of uniQure from a “hold” rating to a “sell” rating in a report on Sunday, January 11th.

Insider Transactions at uniQure

In related news, Director Jack Kaye sold 38,810 shares of the stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total value of $1,177,495.40. Following the completion of the transaction, the director owned 20,439 shares of the company’s stock, valued at approximately $620,119.26. This represents a 65.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Robert Gut sold 31,434 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $27.26, for a total value of $856,890.84. Following the sale, the director owned 40,145 shares of the company’s stock, valued at approximately $1,094,352.70. This trade represents a 43.92% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 102,247 shares of company stock valued at $2,839,298. 4.79% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Institutional investors have recently made changes to their positions in the business. Jefferies Financial Group Inc. acquired a new stake in shares of uniQure during the second quarter worth approximately $29,217,000. JPMorgan Chase & Co. boosted its stake in uniQure by 471.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after acquiring an additional 1,491,486 shares during the last quarter. Fred Alger Management LLC acquired a new position in uniQure during the 3rd quarter worth $75,320,000. Sofinnova Investments Inc. grew its holdings in uniQure by 185.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock worth $21,723,000 after acquiring an additional 1,012,585 shares in the last quarter. Finally, Avoro Capital Advisors LLC increased its position in shares of uniQure by 22.6% in the 3rd quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock worth $259,422,000 after purchasing an additional 819,444 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Stock Performance

NASDAQ:QURE opened at $21.74 on Monday. The firm’s fifty day simple moving average is $24.37 and its 200 day simple moving average is $27.98. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.23. uniQure has a twelve month low of $7.76 and a twelve month high of $71.50. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -4.95 and a beta of 0.68.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. As a group, equities research analysts expect that uniQure will post -3.75 earnings per share for the current fiscal year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.